Traws Pharma (TRAW) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on respiratory viral diseases and cancer, with programs targeting influenza, SARS-CoV-2, and refractory endometrial cancer.

• Acquired Trawsfynydd Therapeutics in April 2024 and changed name to Traws Pharma, Inc.

• Lead assets include a CAP-dependent inhibitor for influenza, an oral antiviral for SARS-CoV-2, and a multi-kinase CDK4-plus inhibitor for cancer.

Financial performance and metrics

• As of September 30, 2024, reported a stockholders' deficit of approximately $2.033 million, below the Nasdaq minimum equity requirement.

• Recent private placement raised capital through the issuance of Class A and Class B Units, each including shares or warrants.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; proceeds from warrant exercises, if any, will be used for product development and general working capital.